Ratziu, Vlad

Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?

Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 88

Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases

Nascimbeni, F., Lebray, P., Fedchuk, L., Oliveira, C. P., Alvares-da-Silva, M. R., Varault, A., Ingiliz, P., Ngo, Y., de Torres, M., Munteanu, M., et al. (2015) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography

Cited by 82

Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis

Hoffmann, C., Djerir, N. E. H., Danckaert, A., Fernandes, J., Roux, P., Charrueau, C., Lachagès, A.-M., Charlotte, F., Brocheriou, I., Clément, K., et al. (2020) · Scientific Reports

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 78

A critical review of endpoints for non-cirrhotic NASH therapeutic trials

Ratziu, V. (2018) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 74

Rational combination therapy for NASH: Insights from clinical trials and error

Ratziu, V., & Charlton, M. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 71

Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis

Vacca, M., Leslie, J., Virtue, S., Lam, B. Y. H., Govaere, O., Tiniakos, D., Snow, S., Davies, S., Petkevicius, K., Tong, Z., et al. (2020) · Nature Metabolism

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 60

Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease

Munteanu, M., Pais, R., Peta, V., Deckmyn, O., Moussalli, J., Ngo, Y., Rudler, M., Lebray, P., Charlotte, F., Thibault, V., et al. (2018) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 42

NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

Rasmussen, D. G. K., Anstee, Q. M., Torstenson, R., Golding, B., Patterson, S. D., Brass, C., Thakker, P., Harrison, S., Billin, A. N., Schuppan, D., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentStatistical Methods in Clinical Trials

Cited by 41

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience

Liver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry Studies

Cited by 28

Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Cazanave, S. C., Warren, A. D., Pacula, M., Touti, F., Zagorska, A., Gural, N., Huang, E. K., Sherman, S., Cheema, M., Ibarra, S., et al. (2021) · Science Translational Medicine

Liver Disease Diagnosis and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 23

A diagnostic proposal for sarcopenic obesity in adults based on body composition phenotypes

Zambon Azevedo, V., Ponnaiah, M., Bel Lassen, P., Ratziu, V., & Oppert, J.-M. (2022) · Clinical Nutrition ESPEN

Nutrition and Health in AgingBody Composition Measurement Techniques

Cited by 18

TOP-289 Artificial intelligence-based measurement of non-alcoholic steatohepatitis is an accurate tool for clinical trial enrollment and end point assessment

Pulaski, H., Hou, H., Resnick, M., Harrison, S. A., Sanyal, A. J., Ratziu, V., Burt, A., Bedossa, P., Montalto, M., & Wack, K. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentArtificial Intelligence in Healthcare and Education

Cited by 1